Feb 25, 2021 9:29am EST JanOne Announces Definitive Agreement to Sell its Legacy Recycling Business for $25 Million
Sep 24, 2020 10:45am EDT JanOne Successfully Begins Production of JAN101 cGMP Batch for Phase 2b Peripheral Artery Disease (PAD) Trial and Potential Covid-19 Study
Sep 22, 2020 9:45am EDT JanOne Issues September 2020 Shareholder Letter Updating Investors on Recent Pharma Asset Potential for Peripheral Artery Disease
Sep 03, 2020 10:30am EDT JanOne confirms stability data of JAN101 development batch and prepares for commercial GMP production to support the upcoming PAD and potential Covid-19 clinical trials
Aug 28, 2020 2:34pm EDT JanOne Selects Partner for Bottling and Labeling of JAN101 for Peripheral Artery Disease and Potential Covid-19 Clinical Trials
Aug 26, 2020 9:45am EDT JanOne Advances its Potential Peripheral Artery Disease and Covid-19 Vascular Inflammation Treatment Towards Trial Readiness
Aug 21, 2020 10:31am EDT JanOne to Host Telebriefing to Discuss Drug Candidate JAN101 for Treatment of Peripheral Artery Disease (PAD) and Potential Applications for COVID-19 Vascular Complications
